OS Therapies Announces Clinical Update From Ongoing Phase 2b Clinical Trial Of Its Immunotherapy OST-HER2 (OST31-154) In Patients With Resected, Recurrent Osteosarcoma
Portfolio Pulse from Benzinga Newsdesk
OS Therapies announced a positive clinical update for its Phase 2b trial of OST-HER2 (OST31-154) in patients with resected, recurrent osteosarcoma. The trial showed a 1-year Event Free Survival (EFS) of 32.5% compared to 20% for the comparator, and an interim 1-year and 18-month Overall Survival (OS) of 90.4%. No severe treatment-related adverse events were reported. The trial is fully enrolled with 41 patients, and primary endpoint data will be released in Q4 2024.
June 03, 2024 | 4:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
OS Therapies announced positive interim results from its Phase 2b trial of OST-HER2 in recurrent osteosarcoma, showing improved survival rates and no severe adverse events. Full data will be released in Q4 2024.
The positive interim results, including improved survival rates and no severe adverse events, are likely to boost investor confidence in OS Therapies. The anticipation of full data in Q4 2024 could sustain interest in the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100